We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




UK Plans Huge Genetic Census

By Biotechdaily staff writers
Posted on 09 Jan 2003
A US$120 million project, called UK Biobank and involving around 500,000 citizens, is being planned by the UK government and medical agencies. More...
The goal of the 10-20 year project is to accumulate information from blood samples and questionnaires that will show how environmental factors, personal habits, and genes can alter genetic susceptibility to disease, thereby enabling doctors to quantify an individual's risk of developing various diseases. The Biobank is scheduled to be ready for use in 2014. The project is being financed by the Wellcome Trust and the Medical Research Council.

The project will be similar to that being conducted in Iceland. However, Iceland has a very homogeneous population. The UK has a much more diverse population, so its findings will be of value to people all over the world. The project is not without detractors. Some critics worry about invasion of privacy. Others worry about pharmaceutical companies being given access to the records. A number of scientists also believe such a large project is not needed. They say similar information can be obtained from a much smaller study.

In other parts of Europe, similar programs are under way. Sweden, Estonia, and Latvia have begun genetic databases. The European Prospective Investigation into Cancer (EPIC) database, begun in 1992, is now in 10 countries.

In the United States, the Mayo Clinic has a similar project just beginning, which is gathering DNA from around 200,000 people. There are a number of other US studies that will offer similar kinds of information. These include the Framingham Heart Study, which has DNA samples of 4,000 people; the Nurses Health Study, with more than 120,000 people enrolled; and the American Cancer Society, with 110,000 DNA samples. Several new studies are scheduled, including a study of 100,000 US children.



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.